Mankind Pharma is expanding its global pharmaceutical business through a strategic investment in next-generation cancer therapies. Through its subsidiary, Mankind Pharma (Netherlands) B.V., the company has entered into a definitive agreement to acquire a 70% stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotechnology company developing advanced chimeric antigen receptor T-cell (CAR-T) therapies for cancer. As part of the transaction, Mankind Pharma will invest €48 million in ACTx. This investment marks a strategic step towards building a global, innovation-led pharmaceutical business and expanding its presence in complex and chronic disease treatment.
Armed Cell Therapeutics Develops Next-Generation CAR-T Therapies
Armed Cell Therapeutics has a pipeline of next-generation CAR-T therapy candidates, with lead programmes targeting non-Hodgkin lymphoma and small cell lung cancer. The company aims to advance innovative approaches to CAR-T cell therapy, including in vivo CAR-T cell generation. Its research and development activities are supported by experienced teams based in the United States and Europe. Through this partnership, Mankind Pharma will gain access to differentiated scientific platforms, an established research team and the potential to develop multiple next-generation CAR-T therapy candidates.
CAR-T Innovation Aims to Overcome Cancer Treatment Challenges
CAR-T cell therapies have transformed the treatment of certain blood cancers. However, some patients experience relapse because CAR-T cells do not persist long enough, lose their effectiveness through exhaustion, or fail to eliminate cancer cells that develop resistance. Moreover, solid tumours present additional challenges because CAR-T cells may struggle to penetrate tumour tissue and function effectively within the hostile tumour microenvironment.
Armed Cell Therapeutics aims to address these limitations through engineered CAR-T cells equipped with additional biological payloads designed to strengthen and sustain their anti-tumour activity. These approaches seek to deliver deeper and more durable treatment responses. Additionally, targeting multiple cancer antigens could make it more difficult for cancer cells to evade treatment. The company is exploring these strategies to expand the potential of CAR-T therapies across different cancer types.
Experienced Leadership to Drive Research and Development
Armed Cell Therapeutics was founded by leaders with extensive experience in drug development, cell therapy and biotechnology company building.
Its leadership includes:
Dr. Paul Stoffels, Chair of the Board: Former Chief Executive Officer of Galapagos and former Chief Scientific Officer of Johnson & Johnson.
Dr. John Mellors, Chief Scientific Officer: Distinguished Professor of Medicine at the University of Pittsburgh and former Senior Vice President of Discovery and Early Development at Galapagos.
Peter Verhaeghe: Former Chair of argenx.
Their combined experience in pharmaceutical research, drug development and biotechnology is expected to support the advancement of ACTx’s research pipeline.
Mankind Pharma Reinforces Its Global Innovation Strategy
The partnership supports Mankind Pharma’s ambition to become an innovation-driven healthcare company with a stronger global presence. By investing in advanced cell therapies, the company aims to expand its capabilities in specialised treatment areas while maintaining its commitment to quality, affordability and accessibility. Arjun Juneja, Chief Operating Officer of Mankind Pharma Ltd., said innovation would be a key driver of the company’s growth over the coming decades. He described the investment as the first step towards building a global pipeline of breakthrough therapies. He added that the partnership would provide access to advanced scientific platforms, experienced leadership and opportunities to develop multiple next-generation CAR-T candidates. In the long term, Mankind Pharma aims to contribute to global scientific innovation and make transformative therapies more accessible to patients in India and worldwide.
ACTx Sees Potential to Expand Access to Advanced Cancer Therapies
Dr. Paul Stoffels, Chair of the Board of Armed Cell Therapeutics, highlighted the potential of next-generation CAR-T therapies to reach more patients by improving treatment potency and durability. He said the company had the scientific assets and experienced team needed to advance these therapies, supported by Mankind Pharma’s investment. He also expressed his commitment to supporting the company’s leadership and strategic development.
Partnership Opens New Opportunities in Cell Therapy
Mankind Pharma’s investment in Armed Cell Therapeutics represents a significant step in its expansion into advanced cancer treatment. By combining financial backing with specialised scientific expertise, the partnership aims to accelerate the development of next-generation CAR-T therapies. As per the press release, as research progresses, these programmes could help address some of the current limitations of cancer cell therapy. However, their clinical effectiveness and broader therapeutic potential will depend on further research and development.